BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

BioVie (BIVI) announced first patient enrollment in the Phase 2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with long COVID. The Company anticipates topline data to be available in the first half of 2026. “Bezisterim has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID, that also play a key role in neurodegenerative diseases of aging, like Parkinson’s and Alzheimer’s. By reducing neuroinflammation and addressing potential metabolic dysfunction, our hope is that bezisterim may have the potential to help patients with long COVID,” stated Cuong Do, BioVie’s President and CEO. “This trial will explore whether targeting these mechanisms can help restore normal function and improve quality of life for individuals affected by the neurological symptoms of long COVID, and we look forward to sharing our findings in the first half of 2026.”